Treatment for newly diagnosed Philadelphia chromosome-positive ALL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a treatment plan for adults with a specific type of acute lymphoblastic leukemia (ALL) that has the Philadelphia chromosome. The goal is to see how well the treatment works and to manage the disease, with some patients also receiving a stem cell transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and have been newly diagnosed with Philadelphia chromosome-positive ALL (or be in blast crisis from CML).
- You must be generally able to care for yourself (performance status 0-2), unless your limitations are due to the leukemia itself.
- Your liver and kidney function must be within acceptable limits, unless the abnormality is caused by the leukemia.
- Your heart function must be normal (ejection fraction greater than 50%), and you must not have severe chronic lung disease.
- You cannot have certain other conditions like chronic liver disease, chronic respiratory failure, kidney failure not caused by ALL, HIV, serious neurological issues (unless from ALL), or a history of pancreatitis or high triglycerides.
- You cannot be pregnant or breastfeeding.
- If you have CML blast crisis, you will always receive a transplant as part of this trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of chemotherapy, targeted pills (imatinib or ponatinib), and a targeted immunotherapy (blinatumomab) before a stem cell transplant for adults with a specific type of leukemia called Philadelphia chromosome-positive ALL. The goal is to find the best treatment approach.
This trial tests a standard chemotherapy regimen for people aged 18 to 50 with a type of leukemia called Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). It aims to see how well the treatment works for this age group.
This trial tests a treatment plan for adults with a type of blood cancer called ALL that is newly diagnosed and not Philadelphia chromosome-positive. The goal is to see how well the treatment works and if it is safe for patients who have not had prior therapy.
This Phase 2 trial tests a combination of medicines to treat Philadelphia chromosome–positive (Ph-positive) or BCR-ABL–positive acute lymphoblastic leukemia (ALL), including cases that have come back or did not respond. It may help by targeting specific leukemia signals while also aiming to improve disease control.
This trial tests a combination of chemotherapy drugs (EPOCH) plus a targeted therapy (ponatinib) for patients with a specific type of acute lymphoblastic leukemia (Ph+ ALL). Some participants also get rituximab if their leukemia cells have a certain marker (CD20). The goal is to see how well this treatment works as a first therapy.
This trial tests a new combination of drugs for adults newly diagnosed with a specific type of acute lymphoblastic leukemia (ALL) that has the Philadelphia chromosome. The goal is to see if this combination is safe and effective in treating the disease.
Hear when a new Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.